Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Apr 28;119(16):2196-201.
doi: 10.1161/CIRCULATIONAHA.108.841197. Epub 2009 Apr 13.

Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients

Gregory Piazza  1 , Erin J Rosenbaum, William Pendergast, Joseph O Jacobson, Robert C Pendleton, Gordon D McLaren, C Gregory Elliott, Scott M Stevens, William F Patton, Ousama Dabbagh, Marilyn D Paterno, Elaine Catapane, Zhongzhen Li, Samuel Z Goldhaber
Affiliations
Randomized Controlled Trial

Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients

Gregory Piazza et al. Circulation. .

Erratum in

  • Circulation. 2010 Jul 6;122(1):e4

Abstract

Background: Venous thromboembolism (VTE) prophylaxis remains underused among hospitalized patients. We designed and carried out a large, multicenter, randomized controlled trial to test the hypothesis that an alert from a hospital staff member to the attending physician will reduce the rate of symptomatic VTE among high-risk patients not receiving prophylaxis.

Methods and results: We enrolled patients using a validated point score system to detect hospitalized patients at high risk for symptomatic VTE who were not receiving prophylaxis. We randomized 2493 patients (82% on Medical Services) from 25 study sites to the intervention group (n=1238), in which the responsible physician was alerted by another hospital staff member, or the control group (n=1255), in which no alert was issued. The primary end point was symptomatic, objectively confirmed VTE within 90 days. Patients whose physicians were alerted were more than twice as likely to receive VTE prophylaxis as control subjects (46.0% versus 20.6%; P<0.0001). The symptomatic VTE rate was lower in the intervention group (2.7% versus 3.4%; hazard ratio, 0.79; 95% CI, 0.50 to 1.25), but the difference did not achieve statistical significance. The rate of major bleeding at 30 days in the alert group was similar to that in the control group (2.1% versus 2.3%; P=0.68).

Conclusions: A strategy of direct notification of the physician by a staff member increases prophylaxis use and leads to a reduction in the rate of symptomatic VTE in hospitalized patients. However, VTE prophylaxis continues to be underused even after physician notification, especially among Medical Service patients.

Trial registration: ClinicalTrials.gov NCT00409136.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES

Gregory Piazza, MD- none

Erin J. Rosenbaum, BA- none

William Pendergast, MD- sanofi-aventis (Research Grant > $10,000, Speaker’s Bureau > $10,000, Consultant/Advisory Board < $10,000); Pfizer (Speaker’s Bureau < $10,000); Novartis (Speaker’s Bureau < $10,000)

Joseph O. Jacobson, MD- none

Robert C. Pendleton, MD- none

Gordon D. McLaren, MD- sanofi-aventis (Research Grant > $10,000); Bristol-Myers Squibb (Research Grant > $10,000)

C. Gregory Elliott, MD- none

Scott M. Stevens, MD- none

William F. Patton, MD- St. Joseph Mercy Health System (Honoraria < $10,000) Ousama Dabbagh, MD- Bristol-Myers Squibb (Research Grant > $10,000); Pfizer (Research Grant > $10,000); Missouri Society of Respiratory Therapists (Honoraria < $10,000)

Marilyn D. Paterno, MBI- none

Elaine Catapane, MEd, MT- none

Zhongzhen Li, MD- none

Samuel Z. Goldhaber, MD- sanofi-aventis (Research Grant > $10,000, Consultant/Advisory Board < $10,000); Eisai (Research Grant > $10,000, Consultant/Advisory Board < $10,000); Boehringer Ingelheim (Research Grant > $10,000, Consultant Advisory Board < $10,000); Bristol-Myers Squibb (Consultant Advisory Board < $10,000)

Figures

Figure 1
Figure 1
Flow of patients through each stage of the trial.
Figure 2
Figure 2
Kaplan-Meier estimates of the absence of symptomatic deep vein thrombosis or pulmonary embolism in the intervention group and the control group (p = 0.31 by the log-rank test for comparison of the outcome between groups at 90 days).
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, Goldhaber SZ. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352:969–977. - PubMed
    1. Kucher N, Castellanos LR, Quiroz R, Koo S, Fanikos J, Goldhaber SZ. Time trends in warfarin-associated hemorrhage. Am J Cardiol. 2004;94:403–406. - PubMed
    1. Kearon C, Ginsberg JS, Hirsh J. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med. 1998;129:1044–1049. - PubMed
    1. Stein PD, Fowler SE, Goodman LR, Gottschalk A, Hales CA, Hull RD, Leeper KV, Jr, Popovich J, Jr, Quinn DA, Sos TA, Sostman HD, Tapson VF, Wakefield TW, Weg JG, Woodard PK. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med. 2006;354:2317–2327. - PubMed
    1. Bates DW, Gawande AA. Improving safety with information technology. N Engl J Med. 2003;348:2526–2534. - PubMed

Publication types

Associated data